Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Public ClinicalTrials.gov record NCT04862663. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Study identification
- NCT ID
- NCT04862663
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 893 participants
Conditions and interventions
Interventions
- Capivasertib Drug
- Fulvestrant Drug
- Palbociclib Drug
- Ribociclib Drug
- Abemaciclib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 10, 2021 (Actual)
- Primary completion
- Nov 1, 2027 (Estimated)
- Completion
- Aug 14, 2029 (Estimated)
- Last update posted
- Aug 17, 2026
2021 – 2029
United States locations
- U.S. sites
- 40
- U.S. states
- 21
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tucson | Arizona | 85719 | — |
| Research Site | Fountain Valley | California | 92708 | — |
| Research Site | Glendale | California | 91204 | — |
| Research Site | Los Angeles | California | 90033 | — |
| Research Site | Napa | California | 94558 | — |
| Research Site | San Francisco | California | 94158 | — |
| Research Site | Santa Rosa | California | 92805 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | New Haven | Connecticut | 06510 | — |
| Research Site | Newark | Delaware | 19713 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Annapolis | Maryland | 21401 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Detroit | Michigan | 48236 | — |
| Research Site | Grand Rapids | Michigan | 49503 | — |
| Research Site | Hannibal | Missouri | 63401 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Omaha | Nebraska | 68130 | — |
| Research Site | Camden | New Jersey | 08103 | — |
| Research Site | Mineola | New York | 11501 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Gresham | Oregon | 97030 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Research Site | York | Pennsylvania | 17403 | — |
| Research Site | Greenville | South Carolina | 29607 | — |
| Research Site | Chattanooga | Tennessee | 37404 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Irving | Texas | 75063 | — |
| Research Site | San Antonio | Texas | 78229 | — |
| Research Site | San Antonio | Texas | 78240 | — |
| Research Site | Salt Lake City | Utah | 84106 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
| Research Site | Falls Church | Virginia | 22042 | — |
| Research Site | Midlothian | Virginia | 23114 | — |
| Research Site | Norfolk | Virginia | 23502 | — |
| Research Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 185 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04862663, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04862663 live on ClinicalTrials.gov.